{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chlamydia-uncomplicated-genital/prescribing-information/amoxicillin/","result":{"pageContext":{"chapter":{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin","depth":2,"htmlHeader":"<!-- begin field f245fc37-ccb0-4287-ac69-f3c5e09a44ce --><h2>Amoxicillin</h2><!-- end field f245fc37-ccb0-4287-ac69-f3c5e09a44ce -->","summary":"","htmlStringContent":"<!-- begin item ed48ab3d-21db-4005-a839-cb4bb608a023 --><!-- end item ed48ab3d-21db-4005-a839-cb4bb608a023 -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","lastRevised":"Last revised in January 2021","chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3ec7e146-110b-5f59-9060-01b6b058f230","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field faff3509-1996-428d-9f12-0ff0cd3f549c --><h3>What contraindications and cautions are important with amoxicillin?</h3><!-- end field faff3509-1996-428d-9f12-0ff0cd3f549c -->","summary":"","htmlStringContent":"<!-- begin item c17d4639-2a25-42e0-aa83-2f4b89d395af --><!-- begin field 26a66fa3-80fe-4bdb-aca6-5e8f4ffa1004 --><ul><li><strong>Do not prescribe amoxicillin to people with</strong> a <em>true</em> penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin. </li><li><strong>Prescribe amoxicillin with caution to people with: </strong><ul><li>Hypersensitivity to cephalosporins. </li><li>Renal impairment — reduce the dose of amoxicillin if eGFR less than 10 mL/minute/1.73 m<sup>2</sup></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 26a66fa3-80fe-4bdb-aca6-5e8f4ffa1004 --><!-- end item c17d4639-2a25-42e0-aa83-2f4b89d395af -->","subChapters":[]},{"id":"751c9a63-4143-58ce-a71d-56ecbd89303e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7b30ac86-cacb-4647-91a4-5861eb31de9c --><h3>What are the adverse effects of amoxicillin?</h3><!-- end field 7b30ac86-cacb-4647-91a4-5861eb31de9c -->","summary":"","htmlStringContent":"<!-- begin item 8ce65c26-08ac-4759-bab7-d548bb7708e3 --><!-- begin field 569bafca-5ef6-4797-993d-3c18492c4ef9 --><ul><li>Adverse effects are mainly gastrointestinal and include nausea, vomiting, and diarrhoea. These are usually mild.<br>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</li></ul><!-- end field 569bafca-5ef6-4797-993d-3c18492c4ef9 --><!-- end item 8ce65c26-08ac-4759-bab7-d548bb7708e3 -->","subChapters":[]},{"id":"04e3b620-f360-5f9d-9195-dd5ee9acffd9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 65b1f331-d8f7-4742-ba37-ddf46dadec9e --><h3>What drug interactions are important with amoxicillin?</h3><!-- end field 65b1f331-d8f7-4742-ba37-ddf46dadec9e -->","summary":"","htmlStringContent":"<!-- begin item b0c41867-0c63-4cf4-9ca2-2062bb902ebe --><!-- begin field 4649cf58-a1c3-4d19-aadc-2fe03f6287d7 --><ul><li><strong>Allopurinol </strong>— increased risk of rash when allopurinol is given with amoxicillin. It is not necessary to stop either drug if this occurs.</li><li><strong>Warfarin </strong>— monitor the international normalized ratio (INR) closely during concomitant use. Any significant changes seem to occur after 4 days of concurrent use. Adjust the warfarin dose accordingly.</li><li><strong>Methotrexate </strong>— consider measuring platelet and white cell counts twice weekly for 2 weeks initially, and measure methotrexate levels if toxicity is suspected.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI Medicines Compendium, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">BNF 71, 2016</a>]</p><!-- end field 4649cf58-a1c3-4d19-aadc-2fe03f6287d7 --><!-- end item b0c41867-0c63-4cf4-9ca2-2062bb902ebe -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}